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Abstract
Background: Several computational candidate gene selection and prioritization methods have recently been
developed. These in silico selection and prioritization techniques are usually based on two central approaches - the
examination of similarities to known disease genes and/or the evaluation of functional annotation of genes. Each
of these approaches has its own caveats. Here we employ a previously described method of candidate gene
prioritization based mainly on gene annotation, in accompaniment with a technique based on the evaluation of
pertinent sequence motifs or signatures, in an attempt to refine the gene prioritization approach. We apply this
approach to X-linked mental retardation (XLMR), a group of heterogeneous disorders for which some of the
underlying genetics is known.
Results: The gene annotation-based binary filtering method yielded a ranked list of putative XLMR candidate
genes with good plausibility of being associated with the development of mental retardation. In parallel, a motif
finding approach based on linear discriminatory analysis (LDA) was employed to identify short sequence patterns
that may discriminate XLMR from non-XLMR genes. High rates (>80%) of correct classification was achieved,
suggesting that the identification of these motifs effectively captures genomic signals associated with XLMR
vs. non-XLMR genes. The computational tools developed for the motif-based LDA is integrated into the freely
available genomic analysis portal Galaxy (http://main.g2.bx.psu.edu/). Nine genes (APLN, ZC4H2, MAGED4, MAGED4B,
RAP2C, FAM156A, FAM156B, TBL1X, and UXT) were highlighted as highly-ranked XLMR methods.
Conclusions: The combination of gene annotation information and sequence motif-orientated computational
candidate gene prediction methods highlight an added benefit in generating a list of plausible candidate genes, as
has been demonstrated for XLMR.
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Background
The identification of genes and genetic variants that
result in disease, or contribute to disease susceptibility,
is a critical objective in medical research. Such findings
have contributed to improvements in diagnosis, prog-
nosis and therapy [1]. The typical approach taken for
disease gene discovery for monogenic traits involves the
identification of affected families, genotyping and linkage
analysis. Subsequent fine mapping of the identified
linked region is performed to focus the candidate region
and reduce the number of putative candidate genes, and
mutation detection is done to uncover the genetic cause
of the disorder [2,3]. This approach has been success-
fully used to pinpoint the genetic contributors for over a
thousand diseases, including Huntington disease [4],
Duchenne muscular dystrophy [5] and cystic fibrosis [6].
With the successful identification of disease genes for
many single-gene disorders, the focus has shifted to dis-
eases with a complex, multifactorial etiology [7,8]. The
candidate gene approach has often been used in the
search for complex disease genes, but with the advent of
massively parallel sequencing and genotyping, genome-
wide approaches (such as genome-wide association stu-
dies [GWAS]) are starting to take precedence [9]. How-
ever, these approaches can result in large sets of
potentially implicated genes, with the challenge then
being to identify the actual genes involved with disease
pathogenesis - a potentially laborious and costly
exercise.
Recently, many computational candidate gene selec-
tion and prioritization methods have been developed, in
part to provide new avenues to pinpoint disease genes
or to prioritize genes from a large list of candidates
[10-21]. Most often, one of two approaches is taken to
identify and prioritize putative disease genes - either
investigating similarities (such as sequence resemblance)
to known disease genes or evaluating functional annota-
tion of genes. The first is based on the premise that dif-
ferences exist between disease genes, and other human
genes, including differences in gene sequence and struc-
ture, which can then be utilized to single out candidate
disease genes [13,14,22,23]. This information can also be
used for other objectives such as the discovery of
sequences important in X-chromosome inactivation, and
the subsequent prediction of expression status of indivi-
dual genes [24]. The second is an annotation-based
approach that centers on the hypothesis that similar dis-
eases may be influenced by genes with comparable fea-
tures (such as function). This method relies heavily on
the terms used to describe genes and their related pro-
ducts, and standardized ontologies utilized across data-
bases (such as Gene Ontology (GO) and eVOC) are
imperative to the efficiency of this approach.
In an attempt to increase the probability of correctly
identifying disease related genes by producing a short
list of highly probable candidate genes, a combined
approach could reduce uncertainty. This could be done
by combining multiple independent lines of evidence,
each by itself lacking sufficient power. In this paper, a
previously described method of candidate gene selection
based primarily on gene annotation [25] is complemen-
ted by the evaluation of pertinent DNA sequence motifs
or signatures to refine the gene selection approach [24].
The intercept between these approaches is evaluated,
and the usefulness of combining the two is discussed.
We have applied this approach to X-linked mental retar-
dation (XLMR), a group of related but heterogeneous
disorders for which some of the underlying genetics is
known (reviewed in [26]).
Results
Annotation-based gene prioritization using a binary
filtering method
The complete set of X chromosome genes (a total of
814 X-linked genes; Ensembl v49) was subjected to can-
didate gene selection for XLMR using a previously
described method [25]. Gene annotation terms found to
be relevant to XLMR were identified through literature
and data-mining (a total of 40 terms; summarized in
Table 1). Each term was used as a selection criterion to
populate a gene list (containing all genes within the
Ensembl database annotated with that term). Candidate
genes were then prioritized using a binary evaluation
grid that assessed the term gene lists against the X-
linked gene list, and genes were scored (see Methods for
details) accordingly, and the X-linked gene list was sub-
sequently prioritized for putative involvement in XLMR.
X-linked genes with the most matches to the annota-
tion-derived gene lists (27/40 being the most matches
for any gene) were ranked as strong candidate XLMR
genes. Figure 1 shows the relative enrichment for known
XLMR genes within the prioritized list, both cumula-
tively and as percentage enrichment. Table S1 (Addi-
tional File 1) shows the prioritization of X-linked genes
as XLMR candidates using this approach, serving as a
test for the sensitivity of this approach. The genes
ranked highly by this method (i.e. more terms matched,
therefore stronger support of being a likely candidate)
have a higher enrichment for known XLMR genes than
for non-XLMR genes. Conversely, the enrichment
becomes moderated as one moves lower down the
prioritized list.
By considering the higher ranking genes on the priori-
tized list (signified by an arbitrary cut-off of 10/40
matches), it is observed that 66% (54/82) of known
XLMR genes are present. This signifies a two-fold
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enrichment for XLMR genes (54/255; 0.212) in this
group compared to all currently identified XLMR genes
relative to X-linked genes (82/814; 0.101). Among the
higher ranking genes, there were 201 genes that have
not previously been associated with XLMR, which may
be interesting candidates (Table S2, Additional File 1).
MECP2, a known XLMR causative gene (OMIM
*300005), had the most annotation term matches (27/
40) and matched at least one term in all four nomen-
clature categories used in prioritization (i.e., anatomical
site terms, biological process, animal homology, and
phenotype; see Methods for details). MECP2 is a
widely expressed transcriptional repressor and has two
conserved functional domains, the methyl-CpG binding
domain and the transcription repression domain [27].
MECP2 displays extreme allelic heterogeneity, with
more than 100 different mutations in the MECP2 gene
being described in patients with Rett Syndrome
[28,29]. Further to this, MECP2 mutations have also
been shown to produce non-syndromic male fatal neo-
natal encephalopathy, progressive spasticity and non-
syndromic Angelman and Prader-Willi-like phenotypes
[29-32]. Rett syndrome is a prime example of the locus
heterogeneity associated with XLMR as MECP2 muta-
tions account for only approximately 70-80% of cases,
whereas locus heterogeneity is hypothesized to explain
the occurrence of the syndrome among MECP2 nega-
tive cases [29]. It is therefore likely that other genes
that have been prioritized by the binary ranking
method may be genetic candidates for Rett syndrome
(among other forms of mental retardation).
The dystrophin gene (DMD) was ranked second high-
est (24/40 matches) and mutations in this gene have
been associated with X-linked mental retardation in
some, but not all cases. DMD is one of the largest
known genes, measuring 2.4 Mb, and was identified as
the gene responsible for Duchenne (DMD) and Becker
(BMD) muscular dystrophies. Dystrophin mRNA is
present in brain tissue and is therefore thought to
potentially contribute to mental retardation, as observed
in some DMD patients [33]. Dystrophin in brain is tran-
scribed from a different promoter to that used in mus-
cle. Chelly et al. (1990) [34] demonstrated that the
brain-type promoter of the dystrophin gene is highly
specific to neurons.
Prioritization based on sequence motifs
Gene sets were selected to identify distinguishing
sequence-based features in the immediately upstream
regions of the transcriptions start sites (TSSs) between
Table 1 Annotation terms identified to be pertinent to XLMR using a literature- and data-mining approach
ANNOTATION TERM CATEGORIES1
Anatomical site Biological Process Phenotype Animal model homology
Developmental Development Seizures Phenotype
Liver Transcription Epilepsy Behaviour/Neurological
Central nervous system Metabolism Acidosis Nervous system related
Respiratory Phosphorylation Microcephaly Embryogenesis
Cerebellum Brain development Tremor
Kidney Timing
Hippocampus Pre-Embryonic
Spinal cord Embryonic
Cerebral cortex Fetal
Testis
Brain stem Anatomy
Peripheral nerve 2TS8-9 Ectoderm
Cerebrum TS10-13 Neural Ectoderm
Substantia nigra TS14-26 CNS
Cardiovascular
Adrenal gland
Thyroid
Ovary
Amygdala
Musculoskeletal
Ganglion
Hypothalamus
1These terms were used to extract gene lists that were compared to all X chromosome genes in a binary filtering process. Annotation terms are divided into four
categories based on their ontological classification.
2TS - Theiller stage: A term used to denote the stage of development of a mouse as described by Theiler in “The House Mouse: Atlas of Mouse Development”
(Springer-Verlag, New York, 1989)
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the sets. The X-linked genes were divided into two
groups: genes demonstrated to be involved in XLMR
(prior validated and published research) and genes that
have not been identified as being involved in XLMR
(called non-XLMR - this group would include both
genes not involved in XLMR and genes that have not
yet been discovered to cause XLMR). In this part of the
study, 81 and 486 genes were labeled as XLMR and
non-XLMR genes, respectively. The remaining X-linked
genes were excluded from the analysis because of the
lack of annotated putative transcription start sites. To
consider the effects of the observed nonrandom distri-
bution of XLMR genes along the X chromosome [35,36]
and the possible influence of distinct origins and evolu-
tionary pressures on XLMR genes [37], genes were
labeled as belonging to the X-added region (XAR; repre-
senting evolutionary young strata) or the X-conserved
region (XCR; representing ancestral mammalian X),
determined by their genomic location [38,39] and were
analyzed separately (Table 2).
To detect sequence motifs (hereafter called “oligo-
mers”) that may discriminate XLMR from non-XLMR
genes (separately for XAR and XCR genes), genomic
sequences (hereafter called “subgenomes”) were
compiled to form four subgenomes. They included
regions upstream from the transcription start sites of
each gene (hereafter called “contigs”) and four variable
distances were considered for the contigs: 5 kilobases
(kb), 10 kb, 50 kb, and 100 kb upstream from the TSS of
each gene. If a contig overlapped with a neighboring con-
tig and both shared the same profile (XLMR or non-
XLMR), the two were merged into a single, larger contig.
If a contig overlapped with a contig from the opposite
profile (e.g., XLMR and non-XLMR), then both contigs
were discarded. Finally, if a contig from one profile over-
lapped with any part of a gene that was classified in the
opposite profile, the contig was discarded (Table S3 -
Additional File 1). Because the 3’ portions of genes regu-
late mRNA stability and translational efficiency [40,41]
and play an important role in development and disease
Table 2 Number of genes considered for sequence-based
prioritization
XAR XCR TOTAL
XLMR 25 56 81
Non-XLMR 110 376 486
TOTAL 135 432
Figure 1 Prioritization of genes on the X chromosome as XLMR candidates using a binary filtering process. The effective cumulative
coverage of XLMR genes from lowest to highest ranked categories is depicted (left Y-axis) as well as the percentage of genes that are XLMR-linked
within each of the categories (right Y-axis).
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[42,43], these regions might contain cis-acting sequences
regulating XLMR genes. To address this possibility, we
performed the same analysis using subgenomes involving
regions both upstream and downstream from the TSSs of
genes. We found no distinct difference between the two
approaches in terms of classification success rates (data
not shown). For this reason, we use the subgenomes
derived from the upstream region of the TSSs of genes in
the subsequent analysis.
To identify the overrepresented oligomers in each sub-
genome, the following criteria were considered: first,
each oligomer was required to occur at least ten times
in the subgenome (because each subgenome usually had
at least 10 genes; Table S3) and second, to be retained
for a particular subgenome (e.g. XLMR; XAR), the oligo-
mer was required to occur five times more frequently in
that subgenome compared to the alternative (e.g. non-
XLMR, XAR; because the median value for the gene
ratio between XLMR and non-XLMR subgenomes is ~5;
Table S3). For the analysis described below, only
12-mers within 10 kb, 50 kb, and 100 kb of each gene
were used as they had the highest total number of over-
represented oligomers (Table S4 - Additional File 1);
too few overrepresented oligomers were found in the 5
kb subgenomes, so this scale was omitted from the
further analysis (see Methods for details). Permutation
tests were performed to evaluate the significance of the
overrepresentation of oligomers (Table S5 - Additional
File 1). Subsequently, overlapping (among different
subgenomes) oligomers were merged into longer ones
resulting in 268 (two from XLMR and 266 from
non-XLMR) and 584 (11 from XLMR and 573 from
non-XLMR) overrepresented oligomers found for XAR
and XCR, respectively. Remarkably, the majority of
these oligomers (about 97%) overlapped with known
classes of interspersed elements. There was no clear dif-
ference in sequence classes between XLMR and non-
XLMR. For overrepresented oligomers not mapping to
the interspersed elements, they did not match known
transcription factor binding motifs from the JASPAR
CORE database [44].
Statistical analyses were performed to predict whether,
using the set of overrepresented oligomers, genes could
be classified as putative XLMR genes or non-XLMR
genes. Linear discriminant analysis (LDA [45]) was used
as a classifier to distinguish between XLMR and non-
XLMR genes, considering XAR and XCR genes sepa-
rately. Genes and counts of overrepresented oligomers
upstream from TSSs of genes, identified above, were
used as the units and features for classification. Utilizing
two distinct sets of training data (either genes from the
XAR or XCR), both LDA classifiers achieved classifica-
tion accuracy of greater than 80% for both XLMR and
non-XLMR classes except for the 10 kb range (Table 3).
The high rates of correct classification imply that classi-
fiers based on counts of overrepresented oligomers
effectively capture genomic signals found near XLMR
vs. non-XLMR genes. In the case of the 100 kb range,
correct classification rates for both classifiers were ≥
96% for XLMR and non-XLMR classes (Figure 2 and
Figure 2 LDA classification success rates for different values of the tuning parameter. (A) All XAR genes were used for training and test
sets. (B) All XCR genes were used for training and test sets. Leave-one-out cross-validation was utilized to calculate correct classification rates.
Dots indicate optimal values of τ. More detailed information is given in Table 3.
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Table 3). All genes tested in XAR with the 100 kb dis-
tance were perfectly classified (Table S7 - Additional
File 1). For genes in XCR with the 100 kb distance, two
genes (out of seven) in the XLMR class and three genes
(out of 75) in non-XLMR class were incorrectly classi-
fied. Among these three incorrectly classified genes, one
gene (STARD8) was consistently misclassified an XLMR
gene at 10 kb and 50 kb distances as well, indicating
that this gene may be a strong candidate XLMR gene.
The other two genes that were misclassified with the
100 kb distance - TRO and NUDT10 - were not consis-
tently misclassified across all three distances (Table S7),
which lowers our confidence in them being true candi-
dates. In addition to this there were a further seven
non-XLMR genes that were incorrectly classified as
XLMR-genes at both 10 kb and 50 kb distances (ESX1,
FGF16, ZC4H2, MAMLD1, ODZ1, PAGE4 and
TMEM28).
Combined analysis of annotation-based and sequence
motif assessment in classifying X-linked genes as putative
XLMR genes
To evaluate which genes are classified as high-probabil-
ity XLMR genes by both of the assessment approaches,
a step-wise approach was used. This was first done by
analyzing the 255 top-ranked genes from the annota-
tion-based approach (matching at least 10/40 criteria)
and comparing them to the outcomes of the XLMR vs.
non-XLMR discriminatory sequence-based classifiers.
For this analysis, 154 genes (out of 255) were excluded
from the dataset; either because of the lack of an anno-
tated TSS (18 genes) or because of the short length of
contigs (136 genes; namely, the distance from the TSS
of the gene to its closest neighbor gene was less than
10 kb). The remaining 101 genes with at least 10 kb
contigs were classified as XLMR [46] or non-XLMR
genes and assessed using the sequence-based method to
determine whether they had a XLMR or non-XLMR
signature. In the case of genes whose contig length was
greater than 50 kb (42 genes), 78.6% (33/42) had signa-
tures as expected based on prior knowledge ("correctly
classified” i.e. based on validated knowledge of involve-
ment with XLMR vs. not previously associated with
XLMR), and for contig lengths greater that 100 kb (22
genes), 86.4% (19/22) were correctly classified (Table 4).
Of particular interest would be the high-ranked candi-
dates that had not previously been identified as being
involved with XLMR, yet scored highly as probable
XLMR genes and were therefore considered “incorrectly
classified”, i.e. they were included in the non-XLMR set,
but may actually be XLMR genes. This group of genes
would constitute good candidates for further research in
the context of a mental retardation phenotype. Further
analysis of genes with >50 kb contigs, using the
sequence-based classifiers with the 50 kb and 100 kb
distances, revealed that 14 genes were classified as puta-
tive XLMR genes (Table 5). Five of them are known
XLMR genes (AP1S2, ARHGEF9, BCOR, HUWE1, and
ZDHHC9) and the remaining nine (APLN, ZC4H2,
MAGED4, MAGED4B, RAP2C, FAM156A, FAM156B,
TBL1X, and UXT) are strong candidates for XLMR and
merit further analysis (Table 6). Interestingly, only one
of these nine genes (0.11) is located in the XAR, which
is lower than the relative proportion of XAR genes ana-
lyzed (266/573; 0.46).
The second comparison was to examine all the non-
XLMR genes that had a low predictive score on the
sequence-based LDA within at least two categories (10
Table 4 Number of genes with ten or more matched categories using the annotation approach that were classified
correctly by sequence-based LDA method
Genes classified successfully
Length of contigs Number of genes tested 10 kb (Genes) 50 kb (Genes) 100 kb (Genes)
> 10 kb 101 54.5% (55) 52.5% (53) 52.5% (53)
> 50 kb 42 59.5% (25) 78.6% (33) 88.1% (37)
> 100 kb 22 59.1% (13) 81.8% (18) 86.4% (19)
Table 3 Number of genes for training and success rates of LDA
Set Analyzed Parameter 10 kb (Genes) 50 kb (Genes) 100 kb (Genes)
Training and test set of genes in XAR τ 0.96 0.43 0.4
Success in XLMR 100% (19) 100% (15) 100% (9)
Success in non-XLMR 45% (84) 91% (40) 96% (26)
Training and test set of genes in XCR τ 0.87 0.75 0.62
Success in XLMR 87% (38) 100% (16) 100% (7)
Success in non-XLMR 52% (257) 82% (141) 96% (74)
τ is a tuning parameter, which was selected to maximize the sum of correct classification rates for XLMR and non-XLMR sets
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kb, 50 kb or 100 kb subgenomes) and to compare them
to the scores based on the annotation-based binary fil-
tering method. STARD8 was the only gene that was
consistently misclassified as across all three distances. It
did not receive a particularly high ranking using the
annotation-based approach (6/40) and might have been
overlooked as a putative XLMR gene by this method
alone. The other two genes that were misclassified with
the 100 kb distance - TRO and NUDT10 - were both
highly ranked as candidates using the annotation
Table 5 Classification of genes with > 50 kb contigs that were present in at least ten annotation categories
No of annotation terms matched (/40 HGNC symbol XLMR gene1 50 kb2 100 kb2 Dist (kb)3 Strata
24 DMD 1 NX NX 71.7 XAR
23 GPM6B 0 NX NX 68 XAR
19 AP1S2 1 X X 61.4 XAR
19 FGF13 0 NX NX 157.8 XCR
19 ZDHHC9 1 X NX 60.7 XCR
18 TAF9B 0 NX NX 133 XCR
18 FAM156A 0 X NX 90.8 XCR
18 FAM156B 0 X NX 90.8 XCR
17 ARHGEF9 1 NX X 259.5 XCR
17 TMEM47 0 NX NX 285.5 XAR
16 NAP1L2 0 NX NX 182.7 XCR
16 NSBP1 0 NX NX 80.3 XCR
16 PCSK1N 0 NX NX 56.7 XCR
16 UXT 0 X NX 64.4 XCR
15 BCOR 1 X X 253.8 XAR
15 ENOX2 0 NX NX 155 XCR
15 HUWE1 1 X NX 224.7 XCR
15 LAS1L 0 NX NX 132.8 XCR
15 THOC2 0 NX NX 124 XCR
14 CXorf61 0 NX NX 323.4 XCR
14 TBL1X 0 X NX 190.3 XAR
14 TMLHE 0 NX NX 154.8 XCR
13 C1GALT1C1 0 NX NX 102.9 XCR
13 KAL1 0 NX NX 58.6 XAR
13 PPP2R3B 0 NX NX 237.4 XAR
13 RNF12 0 NX NX 65.4 XCR
13 ZMAT1 0 NX NX 77 XCR
12 GABRE 0 NX NX 103 XCR
12 ZC4H2 0 X NX 431.8 XCR
12 MAGED4 0 NX X 115.6 XCR
12 MAGED4B 0 NX X 115.6 XCR
12 MORC4 0 NX NX 64.2 XCR
12 RAI2 0 NX NX 302.1 XAR
11 APLN 0 X NX 84.5 XCR
11 KLHL13 0 NX NX 83.1 XCR
11 MUM1L1 0 NX NX 93.4 XCR
11 RAP2C 0 X NX 160.1 XCR
11 SLITRK4 0 NX NX 72.2 XCR
11 SYTL4 0 NX NX 88.2 XCR
10 CHRDL1 0 NX NX 300.5 XCR
10 PHF16 0 NX NX 72.4 XAR
10 STAG2 0 NX NX 60.9 XCR
1Indicates if gene is a known XLMR (= 1) or not (= 0)
2X indicates that a gene was classified as an XLMR gene and NX signifies classificiation as a non-XLMR gene.
3Distance from the TSS of gene to its closest neighbor gene
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method - receiving a score of 20/40 and 10/40 respec-
tively. Of the other seven non-XLMR genes that were
incorrectly classified at both 10 kb and 50 kb distances
(ESX1, FGF16, ZC4H2, MAMLD1, ODZ1, PAGE4 and
TMEM28) none received a high-rank score in the anno-
tation method, and would have been missed if the can-
didates were evaluated by only this method.
Discussion
Mental retardation is defined as a disability character-
ized by significant limitations both in intellectual func-
tioning and adaptive behaviour [47]. The importance of
genes on the X-chromosome in the cause of mental
retardation has been recognized for decades, largely due
to the fact that males outnumber females in nearly all
surveys of mental retardation by approximately a third
[48]. For the more than 200 forms of XLMR described,
more than 82 causative genes have been catalogued [46]
and ongoing research means that causative genes are
continually identified [49-52].
Mammalian X and Y chromosomes diverged indepen-
dently after evolving from a pair of autosomes [53-55].
The X chromosome is particularly gene-poor, has an
overall low GC-content compared with the genome
average [38] and is highly enriched for interspersed
repeats. It can be divided into the following evolutionary
domains: the X-added region (XAR) and the X-con-
served region (XCR). In this study we use XLMR as an
example to test a combined gene annotation and
sequence-based assessment model for candidate disease
gene prediction.
The annotation-based gene prioritization method
using binary filtering identified 201 X-linked genes that
were annotated in at least ten out of the 40 categories
chosen as representing biological categories expected to
have a link to XLMR, but which had not previously
been associated with XLMR. The annotation categories
included gene expression site, protein function, related
phenotype and animal homology. Of the top ranked
genes that had not previously been associated with a
mental retardation phenotype, several are compelling
candidates for XLMR based on their function.
The highest ranked novel candidate XLMR gene was
TIMP1 (24/40 matches) that encodes a natural inhibi-
tor of the matrix metalloproteinases (MMP), a group
of peptidases involved in degradation of the extracellu-
lar matrix. TIMP1 was shown to reside within a
genetic hotspot for neurodegenerative disorders on the
X chromosome [56]. It has recently been shown that
MMP9-mediated TIMP1-regulated extracellular pro-
teolysis is a novel mechanism contributing to synaptic
plasticity. It is thought that the MMP9/TIMP1 system
could be involved in a broad range of physiological
and pathological phenomena in various brain regions,
including developmental reorganization of the cerebel-
lum, hippocampus-dependent learning and long-term
potentiation [57].
The major caveat of the annotation-based binary fil-
tering method is that it relies on current gene annota-
tion data in the public domain. These data are
incomplete, but constantly growing, and therefore it is
feasible that the method has a biased probability of
prioritizing better annotated genes, regardless of
whether these genes are relevant to the disease of
interest.
In this study we used an additional evaluation method
that depends on DNA sequence that is readily available
in the public domain, and not on gene annotation, and
would therefore be less biased. This method requires
some information that would allow one to build training
sets of genes to identify motifs that will discriminate
between high probability candidate genes and weak
Table 6 Nine genes highlighted as XLMR candidates by both the annotation and sequence motif method
HGNC
symbol
Description Location Function
FAM156A Family with sequence similarity 156,
member A
Xp11.23 Function Unknown
FAM156B Family with sequence similarity 156,
member B
Xp11.22 Function Unknown
UXT Ubiquitously-expressed transcript Xp11.23-
p11.22
Plays a role in facilitating receptor-induced transcriptional activation [83]
TBL1X Transducin (beta)-like 1X-linked Xp22.3 Plays an essential role in transcription activation mediated by nuclear
receptors [84]
MAGED4 Melanoma antigen family D, 4 Xp11 Mainly tumour cell proliferation [85]
MAGED4B Melanoma antigen family D, 4B Xp11 Mainly tumour cell proliferation [85]
ZC4H2 Zinc finger, C4H2 domain containing Xq11.1 Hepatocellular carcinoma-associated antigen [38]
APLN Apelin Xq25 Neuropeptide involved in the regulation of body fluid homeostasis and
cardiovascular functions [86]
RAP2C Member of RAS oncogene family Xq25 Involved in serum response element mediated gene transcription [64]
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candidates. We used a prioritization method based on
sequence motifs to explore the feasibility of differentiat-
ing XLMR genes from non-XLMR genes. In order to
construct the training data sets we needed to take into
account the evolutionary origin of segments of the X
chromosome, as explained above. It is known that the X
chromosome can be divided into two evolutionary dis-
tinct domains, XAR and XCR. Therefore, for this inves-
tigation LDA classifiers were constructed for the XAR
and XCR genes separately to consider the possible influ-
ence of distinct origins and evolutionary pressures on
XLMR genes [37]. This showed high rates of correct
classification for known XLMR genes and genes on the
X chromosome not previously associated with XLMR.
We tested whether a classifier trained on XAR genes
could predict the XLMR status of XCR genes, and vice
versa. A low success rate was achieved when each LDA
classifier was used to predict the XLMR status in
another test set (Table S6 and Figure S1 - Additional
Files 1 and 2, respectively). It suggests that each set of
overrepresented oligomers captures distinct genomic
signals for XLMR genes in either the XAR or XCR, but
not both.
Using the sequence-based approach, STARD8 (also
known as DLC3), which is not a known XLMR gene,
was identified as a strong candidate XLMR gene by the
sequence-based classification approach. A partial dele-
tion of STARD8 is associated with the craniofrontonasal
syndrome especially in females [58]. STARD8 is also
involved in the growth and metastasis of tumor cells
[59] as are DLC1 and DLC2. Structurally, this protein is
composed of three protein domains: a sterile a-motif, a
RhoGAP (Rho GTPase-activating protein) domain, and
a START domain (StAR, steroidogenic acute regulatory
protein, related lipid transfer). King and colleagues
(2002) [60] revealed that the StAR is expressed in glia
and neurons of the mouse brain and has a role in the
production of neurosteroids supporting STARD8 as a
tentative biological role player in genetic disorders
related to brain functioning.
One of the limitations of the sequence-based motif
approach is the stipulation that a gene must have an
annotated TSS and must have a region of at least 10 kb
upstream of the TSS that does not overlap with another
gene, in order to be assessed. This meant that out of the
top 255 genes identified using the annotation-based bin-
ary filtering method, less than half (only 101) could be
assessed.
Interestingly, STARD8 was not ranked within the top
255 genes using the annotation criteria as it only
matched six of the 40 annotation criteria used for
assessment. Of these criteria matches four were related
to the anatomical site of expression (pinpointing the
brain as a significant expression location of this gene)
and the other two were related to phenotype similarity
in the mouse. STARD8 is not a very extensively studied
gene, which could explain its relatively low level of
annotation and subsequent poor ranking obtained with
the annotation-based evaluation
Despite these limitations, a set of nine genes not pre-
viously associated with XLMR has emerged as high like-
lihood candidates by both prioritization approaches.
These genes represent the overlap of the highest ranking
genes among those that could be assessed by both
methods. A summary of these genes and their main
functions is found in Table 6. Evaluation of these genes’
function and expression sites, among other features,
reveal that these genes do have some putative link to
mental retardation. First and most importantly, all of
the genes are expressed in the central nervous system or
brain in normal tissues and have all been linked to a
neurological-related phenotype or function in the mouse
model [61]. APLN has been shown to play a critical role
in fluid homeostasis and pressure/volume homeostasis
in the brain [62]. This particular function is of utmost
importance to the developing brain and research has
shown that APLN is involved in modifications of the
microvasculature in the immature brain, affecting cere-
bral blood flow during a hypoxic insult [63]. RAP2C has
a more general function as it forms part of the Ras
family, which regulates a wide variety of cellular func-
tions that include cell growth, differentiation, and apop-
tosis [64]. TBLX1 has previously been associated with
lissencephaly, a rare brain formation disorder caused by
defective neuronal migration resulting in a lack of brain
fold and grooves development [65]. Similarly, UXT has
been shown to interact with RCAN1, which codes for
the Down syndrome candidate region 1 (DSCR1) pro-
tein, and it is thought to play a role in the mental dis-
ability features of this syndrome [66]. It is interesting
that all nine of the prioritized genes also have a link to
cancer. This could indicate an important role in expres-
sion regulation mechanisms such as epigenetic modifica-
tions, RNA interference and nonsense-mediated mRNA
decay in XLMR development. These mechanisms are
often disregulated in cancers, and show redundancy
related to their role in human development and pathol-
ogy [67-69].
One approach to evaluate the credibility of the genes
prioritized by these two methods is to compare them to
the set of XLMR genes recently identified through a
large-scale resequencing project [51]. This study found
six known XLMR genes (AP1S2, CUL4B, BRWD3,
UPF3B, ZDHHC9 and SLC9A6) in which there were
multiple truncating variants, as well as three (SYP,
ZNF711 and CASK) that are new additions to the list of
XLMR genes. Four of the known XLMR genes high-
lighted by the Tarpey et al. [51] study, with the
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exception of BRWD3 and SLC9A6, were also prioritized
as top candidates by the annotation method, as were the
three newly identified genes (Table S2). Due to exclu-
sion criteria for the sequence-motif approach only one
of the three newly identified XLMR genes was evaluated
in that approach (ZNF711), and was not classified as a
likely XLMR candidate.
A recent study [70] describes the prioritization of XLMR
candidates based on spatially mapped gene expression,
and focuses on the 718 genes on the X chromosome
recently resequenced by Tarpey et al. [51]. There is signifi-
cant overlap (P = 2.4 × 10-6 by hypergeometric test: H(k;
N, m, n), where k is intersection genes (33), N is the total
number of genes tested (814), m is the number of genes
targeted by [70] (56; from the best 10% of the prioritized
lists), and n is the given XLMR genes (255)) between the
prioritized genes from this paper and the ones prioritized
by our annotation-based method (Table S2). It should be
noted that this method also provides a novel list of candi-
dates, highlighting the precision challenges of computa-
tional prediction methods, and underscores that the aim
of these methods is to highlight promising candidates.
Although both methods described here have specific
caveats, our approach does yield credible candidates for
XLMR, and the merit of applying candidate gene priori-
tization methods with different areas of focus, in paral-
lel, is demonstrated. Candidate gene prioritization for
XLMR could be further improved by the addition of
further lines of evidence, such as expression data, phylo-
genetic profiles or shared protein motifs.
Conclusion
As information in public databases becomes more com-
plete, gene annotation will improve, increasing the likeli-
hood of detecting appropriate candidates and decreasing
the bias due to uneven annotation of genes. When using
a sequence motif-based approach examining regions
upstream of the TSSs of genes, one is limited in compil-
ing training sets, especially in regions that are gene rich,
resulting in genome overlaps and leading to the exclu-
sion of genes for analysis. More extensive sequenced-
based analysis could investigate other gene regions, for
example the 3’UTRs, for motifs that may be related to
RNAi regulatory mechanisms [71]. While combining
gene annotation information and sequence motif-orien-
tated computational candidate gene prediction methods,
it is possible to identify a set of plausible candidate
genes for disease, as has been demonstrated for XLMR.
Methods
Annotation-based gene prioritization using binary
filtering
A list of HGNC IDs for all genes on the X chromosome
(n = 814) were obtained from Ensembl (v49) and were
prioritized for XLMR candidature using a previously
described computational method [25]. This is a gene
prioritization method based on annotation and genes
are evaluated to establish whether their known features
indicate that they are likely to be involved in a particular
disease. The main strength of this approach is the use of
the eVOC ontology, which is a set of controlled voca-
bularies that merges gene expression data by linking
genome sequence- and expression phenotype informa-
tion. In particular, eVOC incorporates terms describing
the sample source of cDNA, SAGE libraries and labeled
target cDNAs for microarray experiments [72]. eVOC
contains four orthogonal ontologies - anatomical system,
cell type, pathology and developmental stage.
Annotation terms were divided into four categories
based on their ontological classification (Table 1) - ana-
tomical site, function, phenotype and animal homology
(no category takes precedence over another). Each term
was then used as a selection criterion to populate a gene
list (containing all genes within the Ensembl database
annotated with that term). All X-linked genes were
prioritized for XLMR using a binary evaluation grid.
The most recent list of cloned XLMR genes (obtained
from [46]) was compared to the ranked list to assess the
ability of this approach to identify known XLMR genes.
Gene annotation terms found to be pertinent to XLMR
were identified through literature and data-mining as
follows: PubMed abstracts related to XLMR were
obtained and the literature mining tools Dragon Disease
Explorer and Dragon TF Association Miner (DTFAM)
[73] (Part of Dragon Explorer System (DES), a licensed
tool of OrionCell http://www.orioncell.org) were used to
extract eVOC and GO ontology terms, respectively from
the abstracts. These terms were then used to populate
the annotation term lists, as described above. The cate-
gories of genes that were selected from the mouse data-
base are: genes associated with phenotypes relevant to
XLMR; genes expressed at different prenatal develop-
mental stages and genes expressed in the developing
brain. To populate the genes list related to animal
homology, human orthologues were obtained by mining
the Jackson Laboratory Mouse Genome database [61].
The binary evaluation was performed as follows: A
gene in the X-linked list was assigned a 1 when that
gene was also present in an annotation term list. If the
gene was absent from that list it was assigned a 0. For
each of the X chromosome genes a final binary score
was calculated, simply by summing all binary scores for
each of the terms used. Then all genes were ranked
based on this score, with those having higher scores
being higher in the rank list. Genes in the list that
matched most annotation terms (i.e. those genes that
obtained the most 1-scores in the binary matrix)
received the highest rank as XLMR candidates. Similarly,
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genes that matched very few or none of the terms have
a lower rank and are considered to be weak candidates.
Prioritization based on sequence motifs
To perform the analysis for sequence-based prioritiza-
tion a total 87 non-redundant candidate XLMR genes
were collected from four main sources: Euro-MRX con-
sortium (http://www.euromrx.com/en/database.html; 18
genes), 83 genes from [74], 62 genes from [75] and 69
genes collected from additional experimental literature.
Because it can be difficult to define the candidate non-
XLMR genes, as many genes as possible that are likely
involved in XLMR were considered. The majority of
genes (80 out of 87) gathered here were already utilized
in the annotation-based approach and seven candidate
XLMR genes were additionally obtained. In this analysis,
it was assumed that X-linked genes, excluding the 87
genes listed above, are non-XLMR genes, resulting in
647 X-linked genes being classified as non-XLMR genes.
The reference sets of X-linked genes were obtained
from the UCSC Refseq track (hg18) and the Ensembl
HUGO track (release 48 of NCBI build 36).
The putative TSSs of genes were identified using the
methods described in [76]. Briefly, using data from two
sets of 5’-end-tag-capture technologies (i.e., CAGE [77]
and PET [78]), TSS-tag clusters for genes were identi-
fied. To map the TSS-tag clusters to their corresponding
genes, the following two criteria were considered. First,
the strand of a TSS-tag cluster must be identical to the
strand of a gene. Second, a TSS-tag cluster must be
located in the 5’ upstream region from the coding start
site of a gene. If multiple TSS-tag clusters were identi-
fied for a single gene, then only the TSS-tag site sup-
ported by the highest number of tags was selected to be
used as the representative TSS. If multiple TSS-tag clus-
ters had the same highest tag score, the TSS cluster clo-
sest to the coding start site was chosen to serve as the
representative TSS. To ensure the reliability of the TSS-
tag data, TSS-tag clusters with a single tag were
excluded. Using RefSeq [79], H-Invitational [80] and
human ESTs [81] from the UCSC genome browser ser-
ver (hg18), TSS-tag clusters were also discarded if the
genomic coordinate of the 5’ end of the putatively corre-
sponding cDNAs or ESTs did not overlapped with the
TSS-tag clusters. As a result, putative transcription start
sites for 81 XLMR and 486 non-XLMR genes were
obtained from experimental data.
The motif discovery method used in [24] was adopted to
detect significantly overrepresented oligomers from each
subgenome (i.e., the XLMR and non-XLMR subgenome),
for the XAR and XCR genes separately. Briefly, first all
possible oligomers found within each subgenome were
enumerated and sequentially counted. Five specified sizes
(8-, 12-, 16-, 20-, and 24-mers) of oligomers were
considered. Counts of oligomers were combined with
counts of their reverse complement sequences. Exact
matches were required. To define an oligomer as an over-
represented oligomer, two criteria were used: the oligomer
should (1) occur at least 10 times in the relevant subge-
nome and (2) should be enriched at least five-fold in the
relevant subgenome as compared to the other subgenome
(e.g. to be defined as an oligomer for XLMR using the 10
kb distance as an example, an oligomer must occur at
least five times more often in the 10 kb region upstream
of an XLMR gene vs. the frequency of the same oligomer
in the 10 kb region upstream of a non-XLMR gene). Per-
mutation tests were performed to evaluate whether the
overrepresented oligomers identified were significantly
overrepresented in one subgenome compared to the other.
For this permutation test, the subgenomes (XLMR and
non-XLMR subgenomes) were pooled together and then
divided into nonoverlapping 2 kb fragments. Each 2 kb
fragment was randomly assigned to either a pseudo-
XLMR or a pseudo-non-XLMR subgenome until the two
pseudo subgenomes were equal to the two actual subge-
nomes in size. Within each pseudo subgenome the oligo-
mers that satisfied the above two criteria for
overrepresented oligomers were identified. This process
was repeated 1000 times, and those oligomers that were
identified in fewer than 50 out of the 1000 pseudo subge-
nome trials (p < 0.05) were considered significantly
overrepresented.
LDA analysis was performed as reported in [24] with the
only difference being that the P value for the p-dimen-
sional predictor vector was 268 for XAR and 584 for XCR
classifiers (Table 2). Leave-one-out cross-validation was
utilized to calculate correct classification rates. The com-
putational tools for Principal Component Analysis (PCA),
LDA and ROC visualization were developed and integrated
into a freely available genomic analysis portal, Galaxy
(http://main.g2.bx.psu.edu/ under Statistics tools; [20]).
To evaluate the overrepresented oligomers for poten-
tial functional motifs, we compared them to known
transcription factor binding sites. We aligned the oligo-
mers against all binding sites in JASPAR CORE database
(version 3.0) [44] using MATLIGN [82] with the Eucli-
dean distance scoring function. RepeatMasker tables at
the UCSC Genome Browser (hg18) were utilized to map
the coordinates of transposable elements into the geno-
mic region of X chromosome.
Reviewers’ comments
Reviewer #1: Dr Barbara Bardoni (nominated by Prof
Juergen Brosius)
Institute of Molecular and Cellular Pharmacology,
University of Nice-Sophia Antipolis, Valbonne,
France
This reviewer provided no comments for publication.
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Reviewer #2: Prof Neil Smalheiser
Department of Psychiatry, University of Illinois at
Chicago, Chicago, IL, USA
This manuscript attempts to predict genes that can
cause or contribute to X-linked mental retardation, by
combining annotation-based and sequence-based meth-
ods. The underlying hypothesis is that genes which are
“similar” to known causal genes will be likely to cause
disease too. Although this is a very reasonable idea, the
ms. is currently in very rough shape and the conclusions
are misleading at best.
One problem is that the authors never address a fun-
damental question head-on: What is the expected/esti-
mated total number of genes that they expect to exist
that cause XLMR? What fraction is currently known,
and what fraction of the remaining genes is similar to
those already known? Maybe the vast majority of new
genes to be discovered are NOT similar to those already
known, so their method has quite limited power to dis-
cover. The gene numbers may be related to those given
in Table S1, but they should be clearly discussed in the
text at the outset.
Conversely, it is also possible (even likely) that ALL
genes that are involved in synaptic function or signalling
can cause XLMR when mutated or altered. If so, then
again, their combined method has quite limited power
and scope, and may show marginal improvement over
simply making a list of all genes expressed at synapses.
There are also severe technical issues that should be
resolved, if possible, which will be listed in order that
they were encountered within the manuscript:
1. Their method excludes all noncoding RNAs, as well
as elements (e.g., enhancers) whose effects are not local.
Authors’ Response
Since the method is modular in its design, it could be
adjusted to include any number of addition criteria. In
this paper, we focus on the potential function of protein-
coding genes, as a first-line of evaluation.
2. They acknowledge a “major caveat” in the annota-
tion approach but this may actually be a fatal flaw.
Namely, better studied genes are better annotated, and
genes already known to be involved in disease are better
studied. This probably creates a confound so that the
authors cannot use the fact that known genes are highly
ranked in their schemes as evidence that the method
works well.
Authors’ Response
This is correct; however, more genes are becoming well
annotated. Although known disease genes are often well-
studied, there are several other non-disease genes that
are equally or even better studied. The premise here is
that one expects genes involved in the same disease to
share commonalities in their functional annotation, rela-
tive to other genes in the genome. Some types of
annotation are less likely to be biased as they have been
studies on a genome wide basis (i.e. gene expression site
and animal homology). The method’s modularity means
that more evidence can be added to extend its accuracy
and to strengthen the confidence in a finding (as is illu-
strated here by the addition of sequence motifs as an
extra layer of evidence for candidacy).
3. On p. 8, they note that fully a third of known
XLMR genes fail to be ranked highly by the annotation
scheme, which indicates rather poor performance. An
error analysis should be carried out to see why this is
so, and whether the method can be improved [sequence
based analysis does NOT improve performance since it
was only applied to those genes that ranked highly by
annotation alone].
Authors’ Response
The sequence-based approach was applied to the full
gene set to produce a set of highly-ranked candidates.
These are now listed in Table 2and Table S7. This result
was then compared to the highly-ranked list from the
annotation approach (Table 4, 5, and 6). This approach
has previously been shown to be appropriate for the
investigation of complex disease aetiology due to selection
of multiple most likely disease genes, and can be used to
identify pathways and regulatory networks of aetiological
significance.
4. The genes not known experimentally to cause
XLMR are treated like a negative set, but this is quite
confusing, both technically and in the narrative of the
paper. Really this is a mixed set (some truly negative,
some truly positive but not yet discovered). It is very
confusing to read that putative discoveries are those
which are “incorrectly classified” in the non-XLMR set.
How are those distinguished from errors in the method?
What is the estimated relative numbers of true discov-
eries vs. errors in the “incorrectly classified” set?
Authors’ Response
These sections have been clarified as follows:
“The X-linked genes were divided into two groups:
genes demonstrated to be involved in XLMR (prior vali-
dated and published research) and genes that have not
been identified as being involved in XLMR (called non-
XLMR - this group would include both genes not
involved in XLMR and genes that have not yet been dis-
covered to cause XLMR).”
And also “In the case of genes whose contig length was
greater than 50 kb (42 genes), 78.6% (33/42) had signa-
tures as expected based on prior knowledge ("correctly
classified” i.e. based on validated knowledge of involve-
ment with XLMR vs. not previously associated with
XLMR), and for contig lengths greater that 100 kb (22
genes), 86.4% (19/22) were correctly classified (Table 4).
Of particular interest would be the high-ranked candi-
dates that had not previously been identified as being
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involved with XLMR, yet scored highly as probable
XLMR genes and were therefore considered “incorrectly
classified”, i.e. they were included in the non-XLMR set,
but may actually be XLMR genes. This group of genes
would constitute good candidates for further research in
the context of a mental retardation phenotype.”
5. The sequence based approach is not very promising
as used in this paper, both because it was only applied
to a subset of genes [those that ranked highly by anno-
tation] and because it could only be applied to a minor-
ity of THOSE genes. Even if the combined performance
was perfect, it is not clear that this is a practical method
that can be advocated for others to use and take ser-
iously. As it is, the results do not clearly indicate how
much better the combined method is, compared to each
method alone, in the usual performance parameters
(precision, recall, accuracy, etc.). The data may be there,
but it was not obvious to me. I could not find a legend
for Supplemental File 1.
Authors’ Response
We did apply the sequence based approach for all 567
genes (81 and 486 for XLMR and non-XLMR genes,
respectively; see p. 9-12). After we had done both ana-
lyses, we then scrutinized the 255 top-ranked genes from
the annotation-based approach for their scoring in the
motif-based method. We have now also added the
inverse comparison.
We agree the reviewer that comparisons of the each
method including combined one will be valuable, but
this is not possible at present since we do not know
which additional X-linked genes are currently unknown
XLMR genes. However, our main purpose was to identify
potential candidate XLMR genes using heterogeneous
biological information.
The legend for Supplemental File 1 can be found at the
end of this manuscript, under the heading of Description
of additional data files.
6. In the list of references to prior work, Dmitar Hris-
tovski and others who use implicit (not explicit) similar-
ity should be added.
Authors’ Response
These papers have been added.
Reviewer #3: Dr Dustin Holloway (nominated by Prof
Charles DeLisi)
Boston University Writing Program & Center for the
History and Philosophy of Science, Boston University
General Remarks It has been known for some time that
the combination of orthogonal datatypes (e.g., motif data
and functional annotation) produce results that are
often better than individual methods at predicting the
function of unannotated genes or suggesting their corre-
lation to disease. However, the authors correctly point
out that current GWAS studies are limited in
pinpointing genes and mutations that are truly causative
for disease. Here, the authors use a combination of data
mining, sequence analysis, and pattern recognition algo-
rithms to predict a set of genes that credibly relate to a
specific disease, X-Linked Mental Retardation. Overall,
their report is clear and very well written. The analysis
performed, while not entirely novel was cleverly, metho-
dically, and effectively applied to the specific problem of
discovering candidate disease genes for a particular con-
dition. I feel that their methods are valuable tools in the
hunt for causative disease genes and should be applied
to more disease conditions in the future. Though I
would like to see some further issues discussed in
greater detail (see below), and I would like to see a
more complete analysis of discovered sequence motifs, I
believe that their paper is of publishable quality and will
be of significant value to the community.
Other Comments • Results, paragraph 1: The authors
use data mining to identify terms associated with XLMR
and then use each of those terms to seed a gene list.
The author’s straightforward description doesn’t place
much emphasis on the fact that the ontology used to
derive functional terms (e.g., eVOC) actually contains
information from gene expression studies, sequence
homology, etc. I believe that this information is impor-
tant and increases the significance of their work. Some
functional ontologies (e.g, ECC codes) operate on smal-
ler scales and deal mainly with biochemical function.
The author’s chosen ontologies are broader and incor-
porate a variety of experimental data that are more rele-
vant to the problem they are addressing.
Authors’ Response
The following text was added, to emphasize the use of
the eVOC ontologies in this approach (p23):
The main strength of this approach is the use of the
eVOC ontology, which is a set of controlled vocabularies
that merges gene expression data by linking genome
sequence- and expression phenotype information. In par-
ticular, eVOC incorporates terms describing the sample
source of cDNA, SAGE libraries and labeled target
cDNAs for microarray experiments.
• Do they have a sense of how the varying types of
data contribute to the analysis? That is, do sequence
homology terms, gene expression terms, or GO terms
tend to provide the most prediction power in their
method? In future work, could the ontologies be
improved? What scope do they have for adding addi-
tional datasets?
Authors’ Response
The efficacy of varying types of data in prediction has
not been tested on a test data set, but could be done in
future, and the different prediction terms can then be
weighted to include this knowledge. The scope of this
paper was however not to test the proficiency of
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prediction of any one annotation type, but rather to
assess whether increased efficiency in prediction is
observed when adding more lines of evidence to this
method.
• Methods used by the Authors rely to some extent
on known functional annotations. In the annotation
based analysis, known annotations are required to prior-
itize gene lists. In the motif analysis, known functions
are required to identify positive and negative sets for
motif discovery and LDA. However, there are presum-
ably many additional candidate genes which are poorly
annotated and don’t contain useful transcriptional
motifs and would thus be missed by these methods.
The Authors have created a system which is simple
enough and seems flexible enough to incorporate addi-
tional data. I would suggest a short discussion about
how their method could be expanded to include new
information and expand their ability to address genes of
unknown function. For example, it would probably be
simple to include phylogenetic profiles, or shared pro-
tein motifs (across species) to identify genes that may
be related to disease. They touch on some ideas briefly,
but this could be important future work for their
method.
Authors’ Response
As mentioned before, the method is modular in its design
and can easily include any number of additions.
• In the section discussing “combined analysis” the
authors’ state “Interestingly only one of these nine genes
is located in the XAR.” What is the significance (or
hypothesized significance) of this?
Authors’ Response
The sentence was modified as follows: “Interestingly, only
one of these nine genes (0.11) is located in the XAR,
which is lower than the relative proportion of XAR genes
analyzed (266/573; 0.46).”
• In the discussion, the authors discuss a reference
(their reference 63) which uses spatially mapped gene
expression to identify XLMR genes. The authors note
that the gene set they prepared shows significant overlap
with that of ref. 63. I suggest calculating the statistical
significance of this overlap with a hypergeometric test. If
significant, it would provide additional confidence that
their method is enriching for interesting genes.
Authors’ Response
We added the following to the manuscript:
“There is significant overlap (P = 2.4e-6 by hypergeo-
metric test: H(k; N, m, n), where k is intersection genes
(33), N is the total number of genes tested (814), m is the
number of genes targeted by [70](56; from the best 10%
of the prioritized lists), and n is the given XLMR genes
(255)) between the prioritized genes from this paper and
the ones prioritized by our annotation-based method
(Table S2).”
• For the motif analysis, the authors choose to exam-
ine 12 mers only. Why 12 mers specifically? What about
known transcription factor motifs (e.g., Transfac
motifs)?
Authors’ Response
We mentioned this in the manuscript (p. 11; “only 12-
mers within 10 kb, 50 kb, and 100 kb of each gene were
used as they had the highest total number of overrepre-
sented oligomers (Table S4 - Additional File 1)”).
To evaluate the overrepresented oligomers for potential
functional motifs, we analysed them further and added
the following to the manuscript:
“Remarkably, the majority of these oligomers (about
97%) overlapped with known classes of interspersed ele-
ments. There was no clear difference in sequence classes
between XLMR and non-XLMR. For overrepresented oli-
gomers not mapping to the interspersed elements, they
did not match known transcription factor motifs from
the JASPAR CORE database.”
In addition: The method is included in the appropriate
section.
• The authors identify several hundred over-repre-
sented oligomers in their datasets, but they don’t com-
ment on the sequences themselves. I think it is
important to look at these sequences to decide how bio-
logically relevant they might be. Are many of them simi-
lar, i.e., just variations of a few “core” motifs? Do they
match with or correspond to any known mammalian
transcription factor motifs? Do the motifs appear to be
high in “information content,” meaning that they appear
to be biologically relevant rather than just repeat ele-
ments such as long stretches of GC or A sequence?
Authors’ Response
These issues have been addressed above.
• While LDA is a perfectly valid method for classifica-
tion, did the authors consider alternatives such as SVM
or Random Forest? SVMs offer greater flexibility to
choose non-linear classifiers and also have well estab-
lished kernel methods to handle sequence motif data (e.
g., the spectrum kernel: http://helix-web.stanford.edu/
psb02/leslie.pdf ).
Authors’ Response
While we agree that SVMs tend to offer greater flexibility
than LDA (for example, any distributional assumptions
of datasets (e.g., normal distribution) are not required,
and continuous and qualitative variables in datasets are
controlled well), however, if the main aim of the study is
to extract many more variables (i.e., oligomers) including
discriminative information (conversely, parsimonious and
less variables for SVM) to classify the data as well as to
achieve high classification accuracies, LDA fits well in
this situation. Although we did not show them for our
model in detail due to the small number of oligomers
from XLMR, the use of the LDA has merit and would be
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worth performing as more XLMR genes become
available.
Additional material
Additional File 1: Supplementary tables supporting the analysis.
Additional File 2: Figure S1 - LDA classification success rates for
different values of the tuning parameter τ. (A) Test set of XAR genes,
with training performed on XCR genes. (B) Test set of XCR genes, with
training performed on XAR genes. Leave-one-out cross-validation was
utilized to calculate correct classification rates. Dots indicate optimal
values of τ (see Table S6 - Additional file 1).
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